Overview of tobacco use transitions for population health.


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
05 2020
Historique:
received: 05 09 2019
revised: 14 01 2020
accepted: 15 01 2020
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 3 6 2021
Statut: ppublish

Résumé

The Family Smoking Prevention and Tobacco Control Act provided the US Food and Drug Administration authority to regulate tobacco products using a population health standard. Models have been developed to estimate the population health impacts of tobacco initiation, cessation and relapse transitions. Models should be informed by high-quality, longitudinal data to estimate these constructs. Simulation studies have generated data to predict the impact of various tobacco control interventions, including the influence of regulations on tobacco use behaviours and health. The purpose of this paper is to provide a high-level conceptual overview for understanding tobacco transition behaviours and correlates of these behaviours using data from the Population Assessment of Tobacco and Health (PATH) Study, a US nationally representative longitudinal tobacco study of about 46 000 persons aged 12+ years. The papers that follow in this journal issue build and expand on this conceptual overview using data from the first three waves of the PATH Study. These papers describe use patterns of different tobacco products and their correlates, and can serve as foundations for more in-depth papers that will help the research community better understand the population health impacts and drivers of different tobacco use patterns.

Identifiants

pubmed: 32321846
pii: tobaccocontrol-2019-055367
doi: 10.1136/tobaccocontrol-2019-055367
pmc: PMC7528885
mid: NIHMS1594147
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

s134-s138

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: WMC reports long-term stock holdings in General Electric Company, 3M Company, and Pfizer Incorporated, unrelated to this manuscript. No financial disclosures were reported by the other authors of this paper.

Références

Tob Control. 2020 May;29(Suppl 3):s163-s169
pubmed: 32321850
PLoS One. 2015 Mar 27;10(3):e0121008
pubmed: 25815840
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
Nicotine Tob Res. 2017 Nov 1;19(11):1257-1267
pubmed: 28339561
Tob Control. 2020 May;29(Suppl 3):s191-s202
pubmed: 32321853
Tob Control. 2020 May;29(Suppl 3):s216-s226
pubmed: 32321855
Pediatrics. 2017 Jun;139(6):
pubmed: 28562266
Glob Health Promot. 2016 Jun;23(2 Suppl):3-23
pubmed: 24042975
Addiction. 2017 Jan;112(1):8-17
pubmed: 27109256
Bull World Health Organ. 2000;78(7):868-76
pubmed: 10994259
Int J Environ Res Public Health. 2014 Nov 13;11(11):11691-704
pubmed: 25421063
N Engl J Med. 2018 May 3;378(18):1725-1733
pubmed: 29543114
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847
Tob Control. 2020 May;29(Suppl 3):s178-s190
pubmed: 32321852
N Engl J Med. 2013 Jan 24;368(4):341-50
pubmed: 23343063
Tob Control. 2020 May;29(Suppl 3):s203-s215
pubmed: 32321854
Nicotine Tob Res. 2016 Mar;18(3):229-42
pubmed: 25977409
N Engl J Med. 2017 Jan 26;376(4):342-353
pubmed: 28121512
Tob Control. 2020 May;29(Suppl 3):s170-s177
pubmed: 32321851
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
Drug Alcohol Depend. 2017 Sep 1;178:257-266
pubmed: 28675817

Auteurs

Andrew Hyland (A)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA andrew.hyland@roswellpark.org.

Karin A Kasza (KA)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Nicolette Borek (N)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Heather L Kimmel (HL)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.

Kristie A Taylor (KA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Wilson M Compton (WM)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.

Hannah Day (H)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Elisabeth A Donaldson (EA)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Eva Sharma (E)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Gabriella Anic (G)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Kathryn C Edwards (KC)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Michael J Halenar (MJ)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Lynn C Hull (LC)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Wendy Kissin (W)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Jean Limpert (J)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Elizabeth L Seaman (EL)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Maansi Bansal-Travers (M)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Lisa D Gardner (LD)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Hoda T Hammad (HT)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Cassandra A Stanton (CA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH